A survey presented at ACAAI 2026 shows 77% of US allergists attempt to wean patients off asthma biologics after sustained ...
Research presented at ACAAI 2026 evaluates stock versus personal epinephrine supply requirements, epinephrine availability, ...
Oral remibrutinib demonstrated early and sustained efficacy through 52 weeks across 3 CIndU subtypes in the phase 3 RemIND ...
During the 2026 ACAAI Annual Scientific Meeting, Scott Commins, MD, PhD, describes the clinical nuances and presentation of alpha-gal syndrome, plus emerging developments, including ...
Biennial screening recommended from ages 50 to 69 years for average-risk men, and annual screening recommended for Black men, non-Blacks with strong family history ...
Approval is supported by phase 3 MAJESTY trial results, which demonstrated that Gazyva was superior to tacrolimus in achieving complete remission of proteinuria at 2 years.
Children with atopic dermatitis demonstrate higher odds of sleep problems regardless of co-occurring allergic or psychiatric ...
JAK inhibitor initiation is not more likely to cause incident diabetes than TNF inhibitor initiation in adults with ...
A TriNetX registry study shows GLP-1-based therapies did not improve RA activity and were tied to increased joint pain and ...
Combination osiramestrocel and cartilage acellular matrix injections can rapidly improve pain and function in knee ...